Pulmonary delivery systems for antimicrobial peptides

References

• Butler MS, Gigante V, Sati H, et al. Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother. 2022;66:e0199121.
   PubMed Web of Science ®Google Scholar
• Li J, Zheng H, Leung SSY. Pulmonary delivery of emerging antibacterials for bacterial lung infections treatment. Pharm Res. 2023;40:1057–1072. doi: 10.1007/s11095-022-03379-8.
   PubMed Web of Science ®Google Scholar
• Eldholm V, Balloux F. Antimicrobial resistance in mycobacterium tuberculosis: the odd one out. Trends Microbiol. 2016;24:637–648. doi: 10.1016/j.tim.2016.03.007.
   PubMed Web of Science ®Google Scholar
• Ciofu O, Tolker-Nielsen T, Jensen P, et al. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2015;85:7–23. doi: 10.1016/j.addr.2014.11.017.
   PubMed Web of Science ®Google Scholar
• Klinger-Strobel M, Lautenschläger C, Fischer D, et al. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis – where do we stand? Expert Opin Drug Deliv. 2015;12:1351–1374. doi: 10.1517/17425247.2015.1007949.
   PubMed Web of Science ®Google Scholar
• Huang Z, Kłodzińska SN, Wan F, et al. Nanoparticle mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Deliv Transl Res. 2021;11:1634–1654. doi: 10.1007/s13346-021-00954-1.
   PubMed Web of Science ®Google Scholar
• Garg M, Prabhakar N, Gulati A, et al. Spectrum of imaging findings in pulmonary infections. Part 1: bacterial and viral. Pol J Radiol. 2019;84:e205–e213. doi: 10.5114/pjr.2019.85812.
   PubMed Web of Science ®Google Scholar
• Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton–Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359:753–759. doi: 10.1016/S0140-6736(02)07877-7.
   PubMed Web of Science ®Google Scholar
• D'Anna SE, Maniscalco M, Cappello F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Ann Med. 2021;53:135–150. doi: 10.1080/07853890.2020.1831050.
   PubMed Web of Science ®Google Scholar
• Akinosoglou KS, Karkoulias K, Marangos M. Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2013;17:8–18.
   PubMed Web of Science ®Google Scholar
• Halley A, Leonetti A, Gregori A, et al. The role of the microbiome in cancer and therapy efficacy: focus on lung cancer. Anticancer Res. 2020;40:4807–4818. doi: 10.21873/anticanres.14484.
   PubMed Web of Science ®Google Scholar
• Blair JMA, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13:1–10.
   Web of Science ®Google Scholar
• Zaman SB, Hussain MA, Nye R, et al. A review on antibiotic resistance: alarm bells are ringing. Cureus. 2017;9:e1403. doi: 10.7759/cureus.1403.
   PubMed Web of Science ®Google Scholar
• Register OTF. 2018 CFR Annual Print Title 21 Food and Drugs Parts 300 to 499: intraWEB. Baton Rouge, LA: LLC and Claitor’s Law Publishing; 2018.
   Google Scholar
• GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249. doi: 10.1016/S0140-6736(20)30752-2.
   PubMed Web of Science ®Google Scholar
• Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4:1–37. doi: 10.1128/microbiolspec.VMBF-0016-2015.
   Web of Science ®Google Scholar
• Rončević T, Puizina J, Tossi A. Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era? Int J Mol Sci. 2019;20:2713.
   PubMed Web of Science ®Google Scholar
• (i) Hancock REW, Haney EF, Gill EE. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol. 2016;16:321–334. doi: 10.1038/nri.2016.29.
   PubMed Web of Science ®Google Scholar
  (ii) Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial and host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19:311–332. doi: 10.1038/s41573-019-0058-8.
   PubMed Web of Science ®Google Scholar
  (iii) Drayton M, Deisinger JP, Ludwig KC, et al. Host defense peptides: dual antimicrobial and immunomodulatory action. Int J Mol Sci. 2021;22:11172. doi: 10.3390/ijms222011172.
   PubMed Web of Science ®Google Scholar
• Nordström R, Malmsten M. Delivery systems for antimicrobial peptides. Adv Colloid Interface Sci. 2017;242:17–34. doi: 10.1016/j.cis.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Omar A, Wright JB, Schultz G, et al. Microbial biofilms and chronic wounds. Microorganisms. 2017;5:9. doi: 10.3390/microorganisms5010009.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang RYK, Britton WJ, et al. Advances in the development of antimicrobial peptides and proteins for inhaled therapy. Adv Drug Deliv Rev. 2022;180:114066. doi: 10.1016/j.addr.2021.114066.
   PubMed Web of Science ®Google Scholar
• Chen C, Deslouches B, Montelaro RC, et al. Enhanced efficacy of the engineered antimicrobial peptides WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia. Clin Microbiol Infect. 2018;24:547.e1–547.e8. doi: 10.1016/j.cmi.2017.08.029.
   PubMed Web of Science ®Google Scholar
• Forde E, Kelly G, Sweeney L, et al. Vibrating mesh nebulization of pro-antimicrobial peptides for use in cystic fibrosis. Pharmaceutics. 2019;11:239. doi: 10.3390/pharmaceutics11050239.
   PubMed Web of Science ®Google Scholar
• Forde E, Schütte A, Reeves E, et al. Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis. Antimicrob Agents Chemother. 2016;60:2813–2821. doi: 10.1128/AAC.00157-16.
   PubMed Web of Science ®Google Scholar
• Kwok PCL, Grabarek A, Chow MYT, et al. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. Int J Pharm. 2015;491:367–374. doi: 10.1016/j.ijpharm.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Simonson AW, Umstead TM, Lawanprasert A, et al. Extracellular matrix-inspired inhalable aerogels for rapid clearance of pulmonary tuberculosis. Biomaterials. 2021;273:120848. doi: 10.1016/j.biomaterials.2021.120848.
   PubMed Web of Science ®Google Scholar
• Garcia-Mouton C, Hidalgo A, Cruz A, et al. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur J Pharm Biopharm. 2019;144:230–243. doi: 10.1016/j.ejpb.2019.09.020.
   PubMed Web of Science ®Google Scholar
• Guagliardo R, Perez-Gil J, De Smedt S, et al. Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins. J Control Release. 2018;291:116–126. doi: 10.1016/j.jconrel.2018.10.012.
   PubMed Web of Science ®Google Scholar
• Garcia-Mouton C, Parra-Ortiz E, Malmsten M, et al. Pulmonary surfactant and drug delivery: vehiculization of a tryptophan-tagged antimicrobial peptide over the air–liquid interfacial highway. Eur J Pharm Biopharm. 2022;180:33–47. doi: 10.1016/j.ejpb.2022.09.018.
   PubMed Web of Science ®Google Scholar
• Schmidtchen A, Ringstad L, Kasetty G, et al. Membrane selectivity by W-tagging of antimicrobial peptides. Biochim Biophys Acta. 2011;1808:1081–1091. doi: 10.1016/j.bbamem.2010.12.020.
   PubMed Web of Science ®Google Scholar
• Banaschewski BJ, Veldhuizen EJ, Keating E, et al. Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia. Antimicrob Agents Chemother. 2015;59:3075–3083. doi: 10.1128/AAC.04937-14.
   PubMed Web of Science ®Google Scholar
• Banaschewski BJ, Baer B, Arsenault C, et al. The antibacterial and anti-inflammatory activity of chicken cathelicidin-2 combined with exogenous surfactant for the treatment of cystic fibrosis-associated pathogens. Sci Rep. 2017;7:15545. doi: 10.1038/s41598-017-15558-4.
   PubMed Web of Science ®Google Scholar
• Baer B, Veldhuizen EJ, Molchanova N, et al. Optimizing exogenous surfactant as a pulmonary delivery vehicle for chicken cathelicidin-2. Sci Rep. 2020;10:9392. doi: 10.1038/s41598-020-66448-1.
   PubMed Web of Science ®Google Scholar
• Souza LMP, Nascimento JB, Romeu AL, et al. Penetration of antimicrobial peptides in a lung surfactant model. Colloids Surf B Biointerfaces. 2018;167:345–353. doi: 10.1016/j.colsurfb.2018.04.030.
   PubMed Web of Science ®Google Scholar
• Souza FR, Souza LMP, Pimentel AS. Permeation of beta-defensin-3 encapsulated with polyethylene glycol in lung surfactant models at air–water interface. Colloids Surf B Biointerfaces. 2019;182:110357. doi: 10.1016/j.colsurfb.2019.110357.
   PubMed Web of Science ®Google Scholar
• Creane SE, Carlile SR, Downey D, et al. The impact of lung proteases on snake-derived antimicrobial peptides. Biomolecules. 2021;11:1106. doi: 10.3390/biom11081106.
   PubMed Web of Science ®Google Scholar
• Morris CJ, Beck K, Fox MA, et al. Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery. Antimicrob Agents Chemother. 2012;56:3298–3308. doi: 10.1128/AAC.06335-11.
   PubMed Web of Science ®Google Scholar
• Singh S, Papareddy P, Mörgelin M, et al. Effects of PEGylation on membrane and lipopolysaccharide interactions of host defense peptides. Biomacromolecules. 2014;15:1337–1345. doi: 10.1021/bm401884e.
   PubMed Web of Science ®Google Scholar
• Ilyas H, van der Plas MJA, Agnoletti M, et al. Effect of PEGylation on host defense peptide complexation with bacterial lipopolysaccharide. Bioconjug Chem. 2021;32:1729–1741. doi: 10.1021/acs.bioconjchem.1c00259.
   PubMed Web of Science ®Google Scholar
• Nordström R, Nyström L, Andrén OCJ, et al. Membrane interactions of microgels as carriers of antimicrobial peptides. J Colloid Interface Sci. 2018;513:141–150. doi: 10.1016/j.jcis.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Nyström L, Strömstedt AA, Schmidtchen A, et al. Peptide-loaded microgels as antimicrobial and anti-inflammatory surface coatings. Biomacromolecules. 2018;19:3456–3466. doi: 10.1021/acs.biomac.8b00776.
   PubMed Web of Science ®Google Scholar
• Nordström R, Andrén OCJ, Singh S, et al. Degradable dendritic nanogels as carriers for antimicrobial peptides. J Colloid Interface Sci. 2019;554:592–602. doi: 10.1016/j.jcis.2019.07.028.
   PubMed Web of Science ®Google Scholar
• Insua I, Zizmare L, Peacock AFA, et al. Polymyxin B containing polyion complex (PIC) nanoparticles: improving the antimicrobial activity by tailoring the degree of polymerization of the inert component. Sci Rep. 2017;7:9396. doi: 10.1038/s41598-017-09667-3.
   PubMed Web of Science ®Google Scholar
• Silva JP, Gonçalves C, Costa C, et al. Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment. J Control Release. 2016;235:112–124. doi: 10.1016/j.jconrel.2016.05.064.
   PubMed Web of Science ®Google Scholar
• d’Angelo I, Casciaro B, Miro A, et al. Overcoming barriers in Pseudomonas aeruginosa lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B Biointerfaces. 2015;135:717–725. doi: 10.1016/j.colsurfb.2015.08.027.
   PubMed Web of Science ®Google Scholar
• Casciaro B, d‘Angelo I, Zhang X, et al. Poly(lactide-co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against Pseudomonas aeruginosa lung infection: in vitro and in vivo studies. Biomacromolecules. 2019;20:1876–1888. doi: 10.1021/acs.biomac.8b01829.
   PubMed Web of Science ®Google Scholar
• Falciani C, Zevolini F, Brunetti J, et al. Antimicrobial peptide-loaded nanoparticles as inhalation therapy for Pseudomonas aeruginosa infections. Int J Nanomedicine. 2020;15:1117–1128. doi: 10.2147/IJN.S218966.
   PubMed Web of Science ®Google Scholar
• Song J, Cortez-Jugo C, Shirbin SJ, et al. Immobilization and intracellular delivery of structurally nanoengineered antimicrobial peptide polymers using polyphenol-based capsules. Adv Funct Mater. 2022;6:2107341.
   Google Scholar
• Yang L, Liu Y, Wang N, et al. Albumin-based LL37 peptide nanoparticles as a sustained release system against Pseudomonas aeruginosa lung infection. ACS Biomater Sci Eng. 2021;7:1817–1826. doi: 10.1021/acsbiomaterials.0c01084.
   PubMed Web of Science ®Google Scholar
• Scutera S, Argenziano M, Sparti R, Bessone F, et al. Enhanced antimicrobial and antibiofilm effect of new colistin-loaded human albumin nanoparticles. Antibiotics. 2021;10:57. doi: 10.3390/antibiotics10010057.
   Google Scholar
• Ngambenjawong C, Chan LW, Fleming HE, et al. Conditional antimicrobial peptide therapeutics. ACS Nano. 2022;16:15779–15791. doi: 10.1021/acsnano.2c04162.
   PubMed Web of Science ®Google Scholar
• Li T, Lu XM, Zhang MR, et al. Peptide-based nanomaterials: self-assembly, properties and applications. Bioact Mater. 2022;11:268–282. doi: 10.1016/j.bioactmat.2021.09.029.
   PubMed Web of Science ®Google Scholar
• Veiga AS, Sinthuvanich C, Gaspar D, et al. Arginine-rich self-assembling peptides as potent antibacterial gels. Biomaterials. 2012;33:8907–8916. doi: 10.1016/j.biomaterials.2012.08.046.
   PubMed Web of Science ®Google Scholar
• Salick DA, Pochan DJ, Schneider JP. Design of an injectable β-hairpin peptide hydrogel that kills methicillin-resistant Staphylococcus aureus. Adv Mater. 2009;21:4120–4123. doi: 10.1002/adma.200900189.
   Web of Science ®Google Scholar
• Xu D, Ran Q, Xiang Y, et al. Toward hemocompatible self-assembling antimicrobial nanofibers: understanding the synergistic effect of supramolecular structure and PEGylation on hemocompatibility. RSC Adv. 2016;6:15911–15919. doi: 10.1039/C5RA24553B.
   PubMed Web of Science ®Google Scholar
• Park S-C, Ko C, Hyeon H, et al. Imaging and targeted antimicrobial therapy using chimeric antimicrobial peptide micelles. ACS Appl Mater Interfaces. 2020;12:54306–54315. doi: 10.1021/acsami.0c13083.
   PubMed Web of Science ®Google Scholar
• Liu Y-H, Kuo S-C, Yao B-Y, et al. Colistin nanoparticle assembly by coacervate complexation with polyanionic peptides for treating drug-resistant Gram-negative bacteria. Acta Biomater. 2018;82:133–142. doi: 10.1016/j.actbio.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Akram AR, Avlonitis N, Scholefield E, et al. Enhanced avidity from a multivalent fluorescent antimicrobial peptide enables pathogen detection in a human lung model. Sci Rep. 2019;9:8422. doi: 10.1038/s41598-019-44804-0.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Y. Structure–activity relationship of cationic surfactants as antimicrobial agents. Adv Colloid Interface Sci. 2020;45:28–43. doi: 10.1016/j.cocis.2019.11.009.
   Google Scholar
• Alzahrani NM, Booq RY, Aldossary AM, et al. Liposome-encapsulated tobramycin and IDR-1018 peptide mediated biofilm disruption and enhanced antimicrobial activity against Pseudomonas aeruginosa. Pharmaceutics. 2022;14:960. doi: 10.3390/pharmaceutics14050960.
   PubMed Web of Science ®Google Scholar
• Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm. 2014;477:485–494. doi: 10.1016/j.ijpharm.2014.10.048.
   PubMed Web of Science ®Google Scholar
• Sans-Serramitjana E, Fusté E, Martinez-Garriga B, et al. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros. 2016;15:611–618. doi: 10.1016/j.jcf.2015.12.005.
   PubMed Web of Science ®Google Scholar
• Braun K, Pochert A, Lindén M, et al. Membrane interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides. J Colloid Interface Sci. 2016;475:161–170. doi: 10.1016/j.jcis.2016.05.002.
   PubMed Web of Science ®Google Scholar
• Malekkhaiat Häffner S, Parra-Ortiz E, Browning KL, et al. Membrane interactions of virus-like mesoporous silica nanoparticles. ACS Nano. 2021;15:6787–6800. doi: 10.1021/acsnano.0c10378.
   PubMed Web of Science ®Google Scholar
• Flynn J, Mallen S, Durack E, et al. Mesoporous matrices for the delivery of the broad spectrum bacteriocin, nisin A. J Colloid Interface Sci. 2019;537:396–406. doi: 10.1016/j.jcis.2018.11.037.
   PubMed Web of Science ®Google Scholar
• Malekkhaiat-Häffner S, Nyström L, Browning K, et al. Interaction of laponite with membrane components – consequences for bacterial aggregation and infection confinement. ACS Appl Mater Interfaces. 2019;11:15389–15400. doi: 10.1021/acsami.9b03527.
   PubMed Web of Science ®Google Scholar
• Yu Q, Deng T, Lin FC, et al. Supramolecular assemblies of heterogeneous mesoporous silica nanoparticles to co-deliver antimicrobial peptides and antibiotics for synergistic eradication of pathogenic biofilms. ACS Nano. 2020;14:5926–5937. doi: 10.1021/acsnano.0c01336.
   PubMed Web of Science ®Google Scholar
• Beitzinger B, Gerbl F, Vomhof T, et al. Delivery by dendritic mesoporous silica nanoparticles enhances the antimicrobial activity of a napsin-derived peptide against intracellular Mycobacterium tuberculosis. Adv Healthcare Mater. 2021;10:2100453.
   Web of Science ®Google Scholar
• Tenland E, Pochert A, Krishnan N, et al. Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. PLOS One. 2019;14:e02112858. doi: 10.1371/journal.pone.0212858.
   Web of Science ®Google Scholar
• Rathnayake K, Patel U, Pham C, et al. Targeted delivery of antibiotic therapy to inhibit Pseudomonas aeruginosa using lipid-coated mesoporous silica core-shell nanoassembly. ACS Appl Bio Mater. 2020;3:6708–6721. doi: 10.1021/acsabm.0c00622.
   PubMedGoogle Scholar
• Jin Y, Kim D, Roh H, et al. Tracking the fate of porous silicon nanoparticles delivering a peptide payload by intrinsic photoluminescence lifetime. Adv Mater. 2018;30:e1802878. doi: 10.1002/adma.201802878.
   PubMed Web of Science ®Google Scholar
• Iafisco M, Carella F, Degli Esposti L, et al. Biocompatible antimicrobial colistin loaded calcium phosphate nanoparticles for the counteraction of biofilm formation in cystic fibrosis related infections. J Inorg Biochem. 2022;230:111751. doi: 10.1016/j.jinorgbio.2022.111751.
   PubMed Web of Science ®Google Scholar
• Scherließ R, Bock S, Bungert N, et al. Particle engineering in dry powders for inhalation. Eur J Pharm Sci. 2022;172:106158. doi: 10.1016/j.ejps.2022.106158.
   PubMed Web of Science ®Google Scholar
• Joo HS, Fu CL, Otto M. Bacterial strategies of resistance to antimicrobial peptides. Philos Trans R Soc Lond B Biol Sci. 2016;371:20150292. doi: 10.1098/rstb.2015.0292.
   PubMed Web of Science ®Google Scholar
• Sommer MOA, Munck C, Toft-Kehler RV, et al. Prediction of antibiotic resistance: time for a new preclinical paradigm? Nat Rev Microbiol. 2017;15:689–696. doi: 10.1038/nrmicro.2017.75.
   PubMed Web of Science ®Google Scholar